Veradermics (MANE) Reports Q4 Net Loss of $21.8M

Veradermics, Incorporated (NYSE:MANE) is one of the 8 Healthcare Stocks Insiders Are Buying. On March 30, 2026, Veradermics, Incorporated (NYSE:MANE) reported a Q4 net loss of $21.8M and ended the year with $141.9M in cash, cash equivalents, and marketable securities. CEO Reid Waldman said 2025 was a “landmark year,” highlighting progress in Phase 3 development of VDPHL01 and the company’s IPO, while noting expectations for two Phase 3 readouts in men, continued progress toward an NDA submission, and advancement of a Phase 3 trial for female pattern hair loss.

Earlier in March, Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage on Veradermics, Incorporated (NYSE:MANE) with an Overweight rating, noting the company’s focus on dermatology and its use of “validated biology” of minoxidil with optimized pharmacokinetics to improve efficacy and safety.

Similarly, Leerink initiated coverage on Veradermics, Incorporated (NYSE:MANE) with an Outperform rating and a $75 price target, highlighting the large market for hair loss treatments and positioning VDPHL01 as a potential best-in-class oral therapy for both men and women, supported by a hybrid marketing strategy combining telehealth and direct access.

Veradermics, Incorporated (NYSE:MANE) develops therapies for dermatologic and aesthetic conditions.

While we acknowledge the risk and potential of MANE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MANE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.